Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy.
Biomarker
Hepatitis B
Hepatocellular carcinoma
Nucleos(t)ide analog
Thrombospondin 2
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
15
11
2023
accepted:
15
10
2024
medline:
27
10
2024
pubmed:
27
10
2024
entrez:
27
10
2024
Statut:
epublish
Résumé
Thrombospondin 2 (TSP2) plays a vital role in collagen/fibrin formation, bone growth, vascular density regulation, hemostasis, and cell adhesion. Close associations of serum TSP2 with histological severity in non-alcoholic fatty liver disease and chronic hepatitis C were reported. The present study investigated the significance of circulating TSP2 in chronic hepatitis B patients. Eighty-seven biopsy-proven chronic hepatitis B patients were analyzed in cross-sectional Study 1 to search for correlations between serum TSP2 levels prior to liver biopsy and clinicopathological parameters. In longitudinal Study 2, 51 chronic hepatitis B patients with long-term follow-up (mean: 7.5 years) were examined for changes in serum TSP2 levels during nucleos(t)ide analog (NA) therapy along with trends in hepatocarciongenesis. In Study 1, serum TSP2 levels were not significantly associated with portal inflammation or fibrosis. Study 2 revealed that serum TSP2 was significantly decreased after 48 weeks of NA therapy (P < 0.001). Notably, TSP2 levels at 48 weeks of NA administration (TSP2-48W) were significantly higher in the hepatocellular carcinoma (HCC) (+) group than in the HCC (-) group (P = 0.043). Kaplan-Meier analysis showed that higher TSP2-48W (≥ 24 ng/mL) was associated with future HCC development (P = 0.030). Serum TSP2 levels may be a potential predictor of HCC development in hepatitis B patients receiving NA therapy. Longitudinal prospective studies are necessary to validate our findings.
Identifiants
pubmed: 39461995
doi: 10.1038/s41598-024-76532-5
pii: 10.1038/s41598-024-76532-5
doi:
Substances chimiques
thrombospondin 2
0
Thrombospondins
0
Antiviral Agents
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25584Subventions
Organisme : the joint research program of the Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University
ID : 2024B11
Organisme : Japan Agency for Medical Research and Development
ID : JP23fk0210125
Organisme : Japan Agency for Medical Research and Development
ID : JP24fk0210125
Organisme : Japan Society for the Promotion of Science
ID : JP22K20884
Organisme : Japan Society for the Promotion of Science
ID : JP24K11087
Informations de copyright
© 2024. The Author(s).
Références
Tawada, A., Kanda, T. & Yokosuka, O. Current and future directions for treating hepatitis B virus infection. World J. Hepatol. 7, 1541–1552. https://doi.org/10.4254/wjh.v7.i11.1541 (2015).
doi: 10.4254/wjh.v7.i11.1541
pubmed: 26085913
pmcid: 4462692
Yim, H. J. & Lok, A. S. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 43, S173-181. https://doi.org/10.1002/hep.20956 (2006).
doi: 10.1002/hep.20956
pubmed: 16447285
Ganem, D. & Prince, A. M. Hepatitis B virus infection–Natural history and clinical consequences. N. Engl. J. Med. 350, 1118–1129. https://doi.org/10.1056/NEJMra031087 (2004).
doi: 10.1056/NEJMra031087
pubmed: 15014185
European Association for the Study of the Liver. Electronic address, e. e. e. & European Association for the Study of the, L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67, 370-398, https://doi.org/10.1016/j.jhep.2017.03.021 (2017).
Chang, T. T. et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52, 886–893. https://doi.org/10.1002/hep.23785 (2010).
doi: 10.1002/hep.23785
pubmed: 20683932
Wong, G. L. et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58, 1537–1547. https://doi.org/10.1002/hep.26301 (2013).
doi: 10.1002/hep.26301
pubmed: 23389810
Huang, Z. H. et al. Risk of hepatocellular carcinoma in antiviral treatment-naive chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: A network meta-analysis. BMC Cancer 22, 287. https://doi.org/10.1186/s12885-022-09413-7 (2022).
doi: 10.1186/s12885-022-09413-7
pubmed: 35300634
pmcid: 8930063
Calabro, N. E., Kristofik, N. J. & Kyriakides, T. R. Thrombospondin-2 and extracellular matrix assembly. Biochim. Biophys. Acta 2396–2402, 2014. https://doi.org/10.1016/j.bbagen.2014.01.013 (1840).
doi: 10.1016/j.bbagen.2014.01.013
Iwadare, T. et al. Circulating thrombospondin 2 levels reflect fibrosis severity and disease activity in HCV-infected patients. Sci Rep 12, 18900. https://doi.org/10.1038/s41598-022-23357-9 (2022).
doi: 10.1038/s41598-022-23357-9
pubmed: 36344733
pmcid: 9640666
Kimura, T. et al. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD. Liver Int 41, 505–514. https://doi.org/10.1111/liv.14776 (2021).
doi: 10.1111/liv.14776
pubmed: 33386676
Kozumi, K. et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis. Hepatology 74, 2452–2466. https://doi.org/10.1002/hep.31995 (2021).
doi: 10.1002/hep.31995
pubmed: 34105780
Lee, C. H. et al. Circulating thrombospondin-2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes. Diabetes Care 44, 2089–2097. https://doi.org/10.2337/dc21-0131 (2021).
doi: 10.2337/dc21-0131
pubmed: 34183428
Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology https://doi.org/10.1097/hep.0000000000000466 (2023).
doi: 10.1097/hep.0000000000000466
pubmed: 37401857
Kimura, T. et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J. Gastroenterol. 24, 1440–1450. https://doi.org/10.3748/wjg.v24.i13.1440 (2018).
doi: 10.3748/wjg.v24.i13.1440
pubmed: 29632425
pmcid: 5889824
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20, 15–20 (1994).
Tsukuma, H. et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 328, 1797–1801. https://doi.org/10.1056/nejm199306243282501 (1993).
doi: 10.1056/nejm199306243282501
pubmed: 7684822
Chayanupatkul, M. et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J. Hepatol. 66, 355–362. https://doi.org/10.1016/j.jhep.2016.09.013 (2017).
doi: 10.1016/j.jhep.2016.09.013
pubmed: 27693539
Tseng, T. C. et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142, 1140–1144. https://doi.org/10.1053/j.gastro.2012.02.007 (2012).
doi: 10.1053/j.gastro.2012.02.007
pubmed: 22333950
Adams, J. C. & Lawler, J. The thrombospondins. Cold Spring Harb. Perspect Biol. 3, a009712. https://doi.org/10.1101/cshperspect.a009712 (2011).
doi: 10.1101/cshperspect.a009712
pubmed: 21875984
pmcid: 3179333
Bornstein, P. Thrombospondins as matricellular modulators of cell function. J. Clin. Invest. 107, 929–934. https://doi.org/10.1172/JCI12749 (2001).
doi: 10.1172/JCI12749
pubmed: 11306593
pmcid: 199563
Kimura, T. et al. Thrombospondin 2 is a key determinant of fibrogenesis in non-alcoholic fatty liver disease. Liver Int. 44, 483–496. https://doi.org/10.1111/liv.15792 (2024).
doi: 10.1111/liv.15792
pubmed: 38010940
Tourkochristou, E., Assimakopoulos, S. F., Thomopoulos, K., Marangos, M. & Triantos, C. NAFLD and HBV interplay: Related mechanisms underlying liver disease progression. Front Immunol 13, 965548. https://doi.org/10.3389/fimmu.2022.965548 (2022).
doi: 10.3389/fimmu.2022.965548
pubmed: 36544761
pmcid: 9760931
Saraceni, C. & Birk, J. A review of hepatitis B virus and hepatitis C virus immunopathogenesis. J. Clin. Transl. Hepatol. 9, 409–418. https://doi.org/10.14218/JCTH.2020.00095 (2021).
doi: 10.14218/JCTH.2020.00095
pubmed: 34221927
pmcid: 8237136
Kyriakides, T. R. & Maclauchlan, S. The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J. Cell Commun. Signal 3, 215–225. https://doi.org/10.1007/s12079-009-0077-z (2009).
doi: 10.1007/s12079-009-0077-z
pubmed: 19844806
pmcid: 2778594
Tamaki, N. et al. Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B. JGH Open 8, e13067. https://doi.org/10.1002/jgh3.13067 (2024).
doi: 10.1002/jgh3.13067
pubmed: 38665298
pmcid: 11044154
Hiyama, Y. et al. Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs. Hepatol Res https://doi.org/10.1111/hepr.14042 (2024).
doi: 10.1111/hepr.14042
pubmed: 38539054
Ichikawa, Y. et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol Res 47, 226–233. https://doi.org/10.1111/hepr.12712 (2017).
doi: 10.1111/hepr.12712
pubmed: 27029022
Suh, B. et al. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology 61, 1261–1268. https://doi.org/10.1002/hep.27654 (2015).
doi: 10.1002/hep.27654
pubmed: 25502481
Liao, X., Wang, W., Yu, B. & Tan, S. Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: An integrative pan-cancer analysis. Cancer Cell Int 22, 213. https://doi.org/10.1186/s12935-022-02622-x (2022).
doi: 10.1186/s12935-022-02622-x
pubmed: 35701829
pmcid: 9195477
Byrling, J., Hilmersson, K. S., Ansari, D., Andersson, R. & Andersson, B. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Clin. Transl. Oncol. 24, 297–304. https://doi.org/10.1007/s12094-021-02685-8 (2022).
doi: 10.1007/s12094-021-02685-8
pubmed: 34319497
Matsumae, T. et al. Thrombospondin-2 as a predictive biomarker for hepatocellular carcinoma after hepatitis C virus elimination by direct-acting antiviral. Cancers https://doi.org/10.3390/cancers15020463 (2023).
doi: 10.3390/cancers15020463
pubmed: 36672412
pmcid: 9856394